Friday, December 09, 2016 8:21:44 AM
Re: None
Post #
82688
of 82746 Go
Observations of a small retail AVXL shareholder.
I thank everyone for their postings on this board. Varying viewpoints and perspectives, to be carefully read and considered by those of us with an interest or position in Anavex.
I’m a field biologist and biology instructor, reasonably familiar with the cellular biochemistry of the neuron. None of what I relate here should be construed as investment advice or encouragement; merely the perspectives of an informed small-time retail AVXL investor.
First, I believe and understand that Anavex’s Alzheimer’s treatment approach is unique and wholly different from any drug on the market or under development by any other company. This sets Anavex apart. Its story and future are entirely different from those of any other drug development or sales company. Comparisons with existing Alzheimer’s treatment drugs, about a dozen, with only three or four in common usage, are invalid. None of these have been able to effectively stop or reverse Alzheimer’s symptoms. They merely slow disease progression for a period (often only for a few weeks or months).
As I interpret the available clinical data, Anavex 2-73, in fact, stops symptomatic progression, keeping the disease from progressing to ever more debilitating stages. Yes, the clinical population sizes from which these results are derived are small; but statistically significant, and consistent across the populations. I’m convinced that any future clinical trials of Anavex 2-73 will merely further substantiate the molecule’s unique biochemistry, restoring defective neurons to “homeostasis,” a normalized, fully functioning status. This is accomplished by 2-73's ability to re-connect dislodged or poorly-connected endoplasmic reticula to mitochondria. This restores normalized protein folding in the endoplasmic reticula, creating fully- and normally-functioning reaction-controlling enzymes. With those, neurons will operate healthfully.
All of that is crucial. Other Alzheimer’s drugs attempt to remove A-beta plaques, or tau-tangles, waste protein accumulations found in all Alzheimer’s-affected neurons (but also, incongruously, often in fully healthy people, too). Millions of research dollars have been spent in perfecting and testing waste protein removal drugs; with no success. Many pharmaceutical companies and neurologists persist in this evermore useless pursuit. Anavex has a much better, cheaper, and effective approach. Cause neurons to synthesize functioning enzymes by facilitating normalized endoplasmic reticulum-mitochondria connections.
Another crucial clinical finding. Anavex 2-73 easily crosses the blood-brain barrier, efficiently diffusing into neurons. Few other drugs do this. This allows minimal dosages, in posted clinical trials between 10 and 50 milligrams per day, administered orally (not by injection). Ease of administration, effective in low doses. Extremely useful.
Then, on top of all of this — and it is crucial for FDA approval — Anavex 2-73 has had few or no adverse events in the posted clinical trials. No disqualifying side effects. This is exceptionally rare for any drug or chemical acting inside nerves and neurons. Anavex 2-73 easily gets into neurons, re-connects disconnected endoplasmic reticula with their associated mitochondria, and the neuron then functions normally — without untoward results.
With an understanding all of this I’m convinced the Food and Drug Administration will sooner or later authorize widespread clinical use of Anavex 2-73, at least at the start, for this seminal reason: Anavex 2-73 exceeds any Standard of Care (SOC) results for any existing Alzheimer’s treatment drug. They merely slow for a time (at best) the progression of symptoms. Anavx 2-73 stops symptomatic progression; meaning that if administered at the start of (or before) symptoms, the disease can be chronically suppressed and the patient maintained in a normal mental state. Anavex will become the new Standard of Care drug for Alzheimer’s. No competition.
Eventually, I see widespread prophylactic (preventative) use of 2-73. It may eventually be commonly administered to virtually everyone at the age of 50 or 60, keeping Alzheimer’s from ever developing. No side effects. A small, cheap protein, easily administered.
And, for an expanded story, consider 2-73's eventual treatment or prevention of Parkinson’s disease and other geriatric neurodegenerative diseases. Animal tests indicate equivalent efficacies.
In fact, I suffer (not badly) from hereditary spastic paraplegia (HSP), where the motor neurons of my spine are hyperactive, causing adductor muscles in my thighs to remain tight. I walk with difficulty (but no pain). There is a French report where transgenic rats, with the inserted genetic defect of my disease, were treated with Anavex 2-73 and their spasticity was resolved. Yes, I’m hoping that can eventually happen with me.
I won’t elaborate on the expansive pipeline of other molecules Anavex owns and is developing for other diseases. If only Anavex 2-73 comes to market the company will be a giant success (especially for those of us with equity positions). But I think Anavex 2-73 is the subject of only a few of the early chapters in the eventually more gigantic Anavex story.
Recent BIIB News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 11:31:32 AM
- Biogen Board Appoints Two New Independent Directors • GlobeNewswire Inc. • 09/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 10:00:08 AM
- Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA • GlobeNewswire Inc. • 09/04/2024 11:30:34 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 05:00:40 PM
- Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain • PR Newswire (US) • 08/22/2024 09:10:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/16/2024 10:40:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:30:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:55:02 AM
- Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen • PR Newswire (US) • 07/31/2024 01:00:00 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC • GlobeNewswire Inc. • 07/30/2024 09:15:17 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 20 • PR Newswire (US) • 07/30/2024 09:00:00 PM
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union • GlobeNewswire Inc. • 07/26/2024 11:20:38 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB • PR Newswire (US) • 07/16/2024 08:00:00 AM
- Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB • PR Newswire (US) • 07/12/2024 09:45:00 AM
- July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Biogen Completes Acquisition of Human Immunology Biosciences • GlobeNewswire Inc. • 07/02/2024 01:16:51 PM
- Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News • IH Market News • 06/28/2024 10:50:25 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 06/28/2024 09:45:00 AM
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China • GlobeNewswire Inc. • 06/27/2024 11:39:36 PM
- Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 06/25/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM